Catalog No.
Product Name
Application
Product Information
Citations
-
Drug Impurity
Tramadol impurity 3 hydrochloride is a known impurity of Tramadol hydrochloride, primarily involved in pharmacological studies. This compound is utilized for analytical purposes in the evaluation of drug purity and safety profiles. It serves as a reference standard for the identification and quantification of impurities in Tramadol-related formulations, aiding in compliance with regulatory requirements. -
Drug Impurity
Mirabegron impurity 9 is a chemical impurity associated with the synthesis of the drug Mirabegron. This compound is significant for ensuring the quality and purity of pharmaceutical formulations containing Mirabegron. Its analysis is crucial in research applications focused on drug development and regulatory compliance in the pharmaceutical industry. -
Drug Impurity
Sitagliptin impurity 27 is a known impurity of the DPP-4 inhibitor Sitagliptin. This chemical compound is utilized primarily in analytical and research applications to ensure the purity and quality of Sitagliptin formulations. Its characterization is essential for regulatory compliance and the comprehensive study of drug stability and efficacy in pharmaceutical development. -
Drug Impurity
Atorvastatin impurity 11 sodium is an analytical reference standard associated with atorvastatin sodium. This compound is utilized in research to assess the purity and quality of atorvastatin formulations. Its presence is critical for monitoring pharmacokinetics and ensuring compliance with regulatory standards in pharmaceutical development. -
Drug Impurity
Tramadol impurity 2 hydrochloride is a chemical impurity associated with Tramadol hydrochloride. It serves as an important analytical reference for quality control and impurity profiling in pharmaceutical development. This compound is utilized in research applications to assess the purity of Tramadol formulations and ensure compliance with regulatory standards. -
Drug Impurity
2-(1-Piperazinyl)pyrimidine dihydrochloride is classified as a drug impurity with potential relevance in pharmaceutical development. Its presence may impact the safety and efficacy profiles of drug formulations. This compound is utilized in research applications focused on pharmacokinetics and the assessment of drug purity in quality control processes. -
Tacrolimus Impurity
(E/Z)-FK-506 26,28-Allylic ester rearrangement impurity is a known impurity of Tacrolimus (FK506), a potent immunosuppressive agent. This compound may be utilized in analytical studies focused on the purification and characterization of Tacrolimus, ensuring the quality and safety of pharmaceutical formulations. Its identification and quantification can aid in understanding the stability and degradation pathways of Tacrolimus in various environments. -
Drug Impurity
Hydrocortisone impurity 2 is a drug impurity of Hydrocortisone. This compound is important for analytical studies and quality control in pharmaceutical formulations, aiding in the identification and quantification of impurities in drug products. Its characterization is essential for ensuring the safety and efficacy of Hydrocortisone-based therapies. -
Drug Impurity
Clarithromycin impurity 3 is a known impurity of the antibiotic compound Clarithromycin. This reagent is essential for qualitative analysis and characterization of drug formulations, facilitating the assessment of purity levels in pharmaceutical research. Its presence can impact the efficacy and safety profiles of drug products, making it a valuable tool for quality control and stability studies in drug development. -
Drug Impurity
Regorafenib Impurity 8 is a known impurity associated with Regorafenib, a multi-kinase inhibitor targeting several pathways critical for tumor growth and angiogenesis. This reagent is intended for use in analytical applications, such as characterization and quality control of pharmaceutical formulations. It serves as a reference standard for assessing the purity and stability of Regorafenib in research settings. -
Drug Impurity
Itraconazole impurity 19 is a chemical impurity associated with the antifungal compound Itraconazole. This reagent can be utilized in analytical chemistry for quality control and method validation in pharmaceutical research. Its presence may impact the efficacy and safety assessment of Itraconazole formulations, making it essential for comprehensive characterization studies. -
Drug Impurity
Paliperidone impurity 12, also known as Paliperidone N-oxide, is a drug impurity associated with the synthesis of Paliperidone. This compound serves as a key reference standard for analytical and quality control applications in pharmaceutical research. Its presence may influence the pharmacological properties and safety profiles of formulations containing Paliperidone, making it essential for ensuring the integrity of drug products. -
Drug Impurity
Cetirizine impurity 9 hydrochloride is a chemical impurity associated with Cetirizine hydrochloride. It is primarily utilized in analytical research to evaluate the purity and stability profile of Cetirizine formulations. This compound is essential for quality control processes in pharmaceutical development to ensure compliance with regulatory standards. -
Drug Impurity
Itraconazole impurity 12 is a drug impurity associated with Itraconazole. This chemical compound is utilized primarily in the assessment of the purity and quality control of Itraconazole formulations. Its characterization is essential for regulatory compliance and ensures the safety and efficacy of pharmaceutical products. Research applications include analytical method development and impurity profiling in drug formulation studies. -
Drug Impurity
Azilsartan impurity 11 is a characterized impurity of Azilsartan, an antihypertensive agent. This compound is utilized primarily for quality control and purity assessment in the pharmaceutical research and development of Azilsartan. Its presence may impact the pharmacological properties and safety profile of the drug, making it a crucial component in the analytical evaluation of drug formulations. -
Drug Impurity
Moxifloxacin impurity 6 hydrobromide, also known as 8-Hydroxymoxifloxacin hydrobromide, primarily serves as a drug impurity in analytical research. This compound is relevant for studies focused on the stability and quality assessment of moxifloxacin formulations. Its characterization may aid in understanding the metabolic profile and potential degradation pathways of moxifloxacin in pharmaceutical applications. -
Drug Impurity
Clarithromycin impurity 2 is a known impurity associated with Clarithromycin, a macrolide antibiotic. This reagent can be used for analytical purposes in pharmaceutical research, particularly in studying the purity of Clarithromycin formulations. Its characterization is essential for ensuring quality control and compliance in drug manufacturing processes. -
Drug Impurity
Haloperidol impurity 13, also known as Haloperidol octanoate, is a known impurity of the antipsychotic agent Haloperidol. Its identification and characterization are essential for ensuring the quality and safety of Haloperidol formulations. This compound serves as a valuable reference standard for analytical techniques in pharmaceutical research and quality control. -
Drug Impurity
Everolimus impurity 7 is a chemical impurity associated with the drug everolimus, targeting the mechanistic target of rapamycin (mTOR) pathway. This reagent is essential for analytical research and quality control in the pharmaceutical industry to ensure the purity and safety of everolimus formulations. Use of this impurity facilitates the assessment of drug composition and assists in understanding the effects of impurities on drug efficacy and pharmacodynamics. -
Drug Impurity
Ceritinib impurity 5 is a chemical impurity associated with Ceritinib, an established anaplastic lymphoma kinase (ALK) inhibitor. It serves as an important reference standard for analytical and quality control purposes in pharmaceutical research. This impurity can assist in understanding the stability, degradation pathways, and optimization of Ceritinib formulations. -
Drug Impurity
Mesalazine impurity 6 is a known impurity of the anti-inflammatory drug Mesalazine. It serves as a critical reference compound for quality control and analytical testing in pharmaceutical research. This impurity is essential for validating the purity and integrity of Mesalazine formulations and understanding potential implications in drug efficacy and safety. -
Drug Impurity
Rivastigmine impurity 8 is a chemical impurity associated with the cholinesterase inhibitor rivastigmine. This impurity serves as a reference standard for quality control and analytical applications in pharmaceutical research. It facilitates the identification and quantification of impurities in drug formulations, contributing to the assessment of drug purity and safety in clinical and preclinical studies. -
Drug Impurity
Progesterone Impurity 4, also known as 20-Dihydroprogesterone Acetate, is a known impurity of the hormone progesterone. This compound may be used in quality control and analytical studies to assess the purity of progesterone in pharmaceutical formulations. Its presence can affect the stability and efficacy of progesterone-based products, making it relevant in pharmaceutical and biochemical research applications. -
Drug Impurity
Thioridazine impurity 3, also known as Thioridazine disulfone, is a chemical impurity associated with thioridazine. This compound serves as a vital analytical reference for the characterization and quality control of thioridazine formulations. Its identification is essential for drug development studies and ensuring the integrity of pharmaceutical products containing thioridazine. -
Drug Impurity
Candesartan impurity 30 is a chemical impurity associated with Candesartan, an angiotensin II receptor antagonist. This compound is utilized in quality control and analytical studies to ensure the purity of Candesartan in pharmaceutical formulations. Its evaluation is crucial for maintaining compliance with regulatory standards and for assessing the safety and efficacy of the drug in research applications. -
Drug Impurity
Clindamycin impurity 1 is a known impurity associated with the antibiotic clindamycin. Its presence is primarily of concern in pharmaceutical research and quality control, as it may impact the efficacy and safety profile of clindamycin formulations. This reagent is utilized in analytical studies to ensure the purity of clindamycin and to support regulatory compliance in drug development. -
Drug Impurity
Famotidine impurity 3 hydrochloride is a known impurity of famotidine hydrochloride, primarily utilized in the evaluation of pharmaceutical quality and safety. This compound serves as an important reference material for stability studies, formulation analysis, and impurity profiling in drug development. Its presence is critical for assessing the purity of famotidine formulations and ensuring compliance with regulatory standards in pharmaceutical research. -
Drug Impurity
Afatinib impurity 2 is a characterized impurity associated with the drug Afatinib, a potent irreversible inhibitor of the ErbB family of receptor tyrosine kinases. This impurity is essential for quality control and regulatory compliance in the synthesis of Afatinib, facilitating research on its pharmacological properties and therapeutic applications in oncology. Its presence may impact the overall profile of the parent compound and is crucial for analytical studies in drug development. -
Drug Impurity
Glipizide impurity 14 is a known impurity of the antidiabetic agent Glipizide, primarily affecting the drug's pharmacological profile. This impurity is important for analytical and quality control applications in pharmaceutical research and formulation development. Its characterization is essential for ensuring the safety and efficacy of Glipizide products in clinical settings. -
Drug Impurity
Ranolazine impurity 2 is a chemical impurity associated with the antianginal agent Ranolazine. This compound is utilized in quality control and analytical studies to ensure the purity and safety of pharmaceutical formulations. Its presence and characterization are essential for establishing compliance with regulatory standards in drug development processes. -
Drug Impurity
Famotidine impurity 6 is a chemical impurity associated with Famotidine, a histamine H2-receptor antagonist. This compound is primarily utilized in drug quality control and analysis to ensure the purity and safety of pharmaceutical formulations. Researchers can deploy this reagent in the study of drug synthesis processes and the identification of impurities in H2-antagonist medications. -
Drug Impurity
10-(3-(4-(2-Hydroxyethyl)piperazin-1-yl)propyl)-2-(trifluoromethyl)-10H-phenothiazine 5-oxide, also known as Fludarabine Impurity, is a chemical impurity derived from Fludarabine. This compound retains a phenothiazine structure, demonstrating potential interactions within biological systems. It is primarily utilized in pharmaceutical research to assess purity and identify potential side effects in drug development processes, contributing to the safety and efficacy profiles of therapeutic agents. -
Drug Impurity
Anastrozole impurity 10 is a chemical impurity associated with Anastrozole, which is a non-steroidal aromatase inhibitor primarily targeting the aromatase enzyme. This impurity serves as a critical marker for the quality control and characterization of Anastrozole and related compounds. It is essential for pharmaceutical research and development, particularly in studies evaluating the efficacy and safety of aromatase inhibitors in cancer therapeutics. -
Drug Impurity
Flurbiprofen impurity 5 is a known impurity associated with the nonsteroidal anti-inflammatory drug (NSAID) Flurbiprofen. This compound is utilized in research to study the effects and behaviors of drug impurities, contributing to the understanding of pharmaceutical quality and efficacy. Its analysis is essential for ensuring the safety and effectiveness of drug formulations, particularly within the context of regulatory compliance and drug development. -
Drug Impurity
Famotidine impurity 10 is a known impurity associated with the histamine H2 receptor antagonist famotidine. This compound is utilized primarily in the analysis of drug purity and stability. Its identification is critical in ensuring the quality and safety of pharmaceutical formulations containing famotidine. Researchers may employ this reagent in the assessment of synthesis methods, formulation development, and regulatory compliance. -
Drug Impurity
Mebendazole impurity 6, also known as 5-Benzoyl-2-benzimidazolinone, serves as a drug impurity of Mebendazole. It is utilized in pharmacological studies to ensure the quality and safety of Mebendazole formulations. Understanding this impurity is critical for evaluating the compound's stability and regulatory compliance in drug development. -
Pranoprofen Impurity
2-(5-Oxo-5H-Chromeno[2,3-b]pyridin-7-yl)propanoic acid is a characterized impurity associated with Pranoprofen, a nonsteroidal anti-inflammatory drug. This compound serves as a useful reference standard in analytical chemistry for the assessment of drug purity and stability. Its presence in research can assist in the evaluation of pharmacological profiles and potential safety assessments of pharmaceutical formulations. -
Drug Impurity
Bupropion impurity 3 is a chemical byproduct associated with the synthesis of bupropion. It serves as a crucial reference standard for assessing the purity and quality of bupropion formulations in pharmaceutical research. The compound is essential for analytical studies focusing on the identification and quantification of drug impurities during the development and quality control processes of bupropion. -
Drug Impurity
Cinacalcet impurity 5 is a chemical impurity associated with the drug Cinacalcet, which functions as a calcimimetic agent targeting the calcium-sensing receptor (CaSR). This impurity may serve as a reference standard in quality control and analytical laboratories to ensure the purity of Cinacalcet formulations. Its characterization is crucial for maintaining stringent pharmaceutical standards and for research applications involving drug stability and degradation studies. -
Drug Impurity
Raloxifene impurity 3 is a structural impurity associated with the selective estrogen receptor modulator Raloxifene. It serves as a key reference standard for the assessment of drug purity and formulation quality control in pharmaceutical research. The compound can be utilized in various analytical techniques to ensure compliance with regulatory standards in drug development. -
Drug Impurity
Candesartan impurity 29 is a byproduct associated with the synthesis of Candesartan, an angiotensin II receptor antagonist. This impurity may be utilized in research to assess the purity and stability of Candesartan formulations. Its characterization is essential for quality control and regulatory compliance in pharmaceutical development. -
Drug Impurity
Azilsartan impurity 4 is a chemical impurity associated with the antihypertensive agent Azilsartan. Its characterization is essential for ensuring the quality and safety of drug formulations. This impurity may be used in the development and validation of analytical methods, providing crucial insights into the stability and integrity of Azilsartan compounds in pharmaceutical research. -
Drug Impurity
Clopidogrel impurity 5, also known as Clopidogrel impurity D, is a structural impurity associated with the pharmaceutical compound Clopidogrel. This reagent is critical for studies assessing the purity and quality of Clopidogrel formulations. It is commonly utilized in pharmaceutical research to investigate potential impurities that may influence drug efficacy and safety profiles. -
Drug Impurity
Edoxaban impurity 15 (Edoxaban N-oxide) serves as a drug impurity associated with Edoxaban. This compound is significant for analytical studies concerning drug quality and stability, as well as for assessing the safety and efficacy profiles of Edoxaban formulations. Its characterization is crucial for regulatory compliance in pharmaceutical development and quality control processes. -
Bupivacaine Impurity
1-(2,6-Dimethylphenyl)-6,7-dihydro-1H-azepin-2(5H)-one is identified as an impurity of Bupivacaine, a widely used local anesthetic. This compound may be utilized in quality control and analytical studies to assess the purity of Bupivacaine formulations. Its presence and characterization are essential for ensuring the safety and efficacy of anesthetic preparations in clinical applications. -
Drug Impurity
Trazodone impurity 17 is a specific impurity of the antidepressant Trazodone, primarily associated with the compound's synthesis. It is essential for researchers to evaluate the quality and safety of pharmaceutical formulations, as impurities can influence drug efficacy and safety profiles. This reagent is valuable for analytical studies, quality control, and pharmaceutical development, providing critical insights into the compound's purity and stability. -
Drug Impurity
Moxifloxacin impurity 9 is a drug impurity derived from the antibiotic Moxifloxacin. As an impurity, it is important for quality control and stability testing in pharmaceutical research and development. Its characterization contributes to understanding the synthesis processes and ensuring the safety and efficacy of Moxifloxacin formulations. -
Drug Impurity
Rivaroxaban impurity 13 is a chemical impurity associated with the anticoagulant Rivaroxaban. It is utilized primarily in analytical chemistry for method development and validation, particularly in the assessment of drug purity and quality control. This impurity is essential for researchers examining the stability and safety profiles of pharmaceutical formulations containing Rivaroxaban. -
Drug Impurity
Pantoprazole impurity 26 is a characterized impurity associated with Pantoprazole, a proton pump inhibitor. Its presence is of considerable importance in the pharmaceutical industry for ensuring drug quality and compliance with regulatory standards. This compound is often utilized in analytical research for stability studies, purity assessments, and formulation development. -
Drug Impurity
Canagliflozin impurity 12 is a chemical impurity associated with the antidiabetic agent Canagliflozin, which primarily targets the sodium-glucose co-transporter 2 (SGLT2). This impurity is relevant for quality control and pharmacological assessments in the development of Canagliflozin and related compounds. Research applications include method validation, stability testing, and assessing the purity of pharmaceutical formulations.
